Details for New Drug Application (NDA): 009115
✉ Email this page to a colleague
NDA 009115 describes SERPASIL, which is a drug marketed by Novartis and is included in four NDAs. Additional details are available on the SERPASIL profile page.
The generic ingredient in SERPASIL is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
The generic ingredient in SERPASIL is hydrochlorothiazide; reserpine. There are thirty-two drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.
Medical Subject Heading (MeSH) Categories for 009115
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.25MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 1MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
